// STATE LEGISLATION TRACKER

Arizona HB 2415: kratom products; narcotic drugs

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Passed

State: Arizona
Bill: HB 2415
Session: 57th-2nd-regular
Filed: 2026-01-15
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Arizona HB2415 is about kratom products and narcotic-drug rules, not peptides. Based on the bill title, subjects, and passed status, it does not appear to change compounded peptides, off-label prescribing, telehealth prescribing, NP/naturopath scope, FDA 503A/503B compounding, or prescription monitoring for peptide therapies.

Key Points

No apparent change to compounded peptide access
No apparent change to off-label prescribing rules
No apparent change to telehealth peptide prescribing
No apparent change to NP or naturopath peptide scope
Kratom regulation may matter only if a peptide user also uses kratom

What to Watch For

Note Track whether Arizona later links kratom rules to broader supplement, compounding, or controlled-substance policy.

Note Clinicians should separate kratom compliance from peptide prescribing and compounding compliance.

Concern If kratom-related substances are treated as narcotic drugs, patients using both kratom and peptides may face separate legal risk.

Where the Bill Stands

The listed latest action is PASSED, meaning the bill has cleared the legislative step reported by the source.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws